About the Authors

Carles Gaig

Contributed equally to this work with: Carles Gaig, Dolores Vilas

Affiliations Parkinson’s Disease and Movement Disorders Unit, Neurology Service, Institut de Neurociències Hospital Clínic, University of Barcelona, Barcelona, Spain, Institut d’investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain

Dolores Vilas

Contributed equally to this work with: Carles Gaig, Dolores Vilas

Affiliation Parkinson’s Disease and Movement Disorders Unit, Neurology Service, Institut de Neurociències Hospital Clínic, University of Barcelona, Barcelona, Spain

Jon Infante

Affiliations Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain, Neurology Service, Hospital Universitario Marqués de Valdecilla, University of Cantabria (UC), Santander, Spain

María Sierra

Affiliations Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain, Neurology Service, Hospital Universitario Marqués de Valdecilla, University of Cantabria (UC), Santander, Spain

Inés García-Gorostiaga

Affiliation Neurology Service, Hospital de Galdakao, Usansolo, Vizcaya, Spain

Mariateresa Buongiorno

Affiliations Parkinson’s Disease and Movement Disorders Unit, Neurology Service, Institut de Neurociències Hospital Clínic, University of Barcelona, Barcelona, Spain, Institut d’investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

Mario Ezquerra

Affiliations Parkinson’s Disease and Movement Disorders Unit, Neurology Service, Institut de Neurociències Hospital Clínic, University of Barcelona, Barcelona, Spain, Institut d’investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain

Maria José Martí

Affiliations Parkinson’s Disease and Movement Disorders Unit, Neurology Service, Institut de Neurociències Hospital Clínic, University of Barcelona, Barcelona, Spain, Institut d’investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain

Francesc Valldeoriola

Affiliations Parkinson’s Disease and Movement Disorders Unit, Neurology Service, Institut de Neurociències Hospital Clínic, University of Barcelona, Barcelona, Spain, Institut d’investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain

Miquel Aguilar

Affiliation Neurology Service, Hospital Universitari Mutua de Terrasa, Barcelona, Spain

Matilde Calopa

Affiliation Neurology Service, Hospital Universitari de Bellvitge, Barcelona, Spain

Jorge Hernandez-Vara

Affiliation Neurology Service, Hospital Universitari Vall D’Hebron, Barcelona, Spain

Eduardo Tolosa

etolosa@clinic.ub.es

Affiliations Parkinson’s Disease and Movement Disorders Unit, Neurology Service, Institut de Neurociències Hospital Clínic, University of Barcelona, Barcelona, Spain, Institut d’investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain

Competing Interests

Dr. Tolosa received honoraria for consultancy from Novartis, TEVA, Boehringer Ingelheim, UCB, Solvay, Lundbeck, and TEVA, and he received funding for research from Spaniard Network for Research on neurodegenerative Disorders (CIBERNED)- instituto Carlos III (ISCIII), The Michael J. Fox Foundation for Parkinson’s Research (MJFF), and Fondo de Investigaciones Sanitarias de la Seguridad Social (FISS). Dr. Infante receives research support from the Fondo de Investigación Sanitaria-ISCIII (PI11/00228) and from “Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas” (CIBERNED) (CB06/05/0037). Dr. Sierra receives research support from the Institute for Formation and Research from the Marqués de Valdecilla Foundation-IFIMAV (WLA 04/11) and from “Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas” (CIBERNED) (CB06/05/0037). Dr. Ezquerra was supported by a Miguel Servet contract of the Instituto de Salud Carlos III (ISCIII). Dr. Valldeoriola has received honoraria from Medtronic Ibérica, Boston Scientific, Abbvie Pharmaceutiocals and UCB pharma for lectures and courses. Dr. Gaig, Dr. Vilas, Dr. Buongiorno, Dr. Martí, Dr. García- Gorostiaga, Dr. Aguilar, Dr. Calopa, and Dr. Hernandez-Vara report no disclosures. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: CG DV ET. Performed the experiments: CG DV JI MS IG MA MC JH. Analyzed the data: CG DV JI MS IG ME MB MM FV ET. Contributed reagents/materials/analysis tools: CG DV JI MS IG ME MB MM FV ET. Contributed to the writing of the manuscript: CG DV ET.